Daclizumab

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Gold 2016	Worldwide Until 2015 retrospective cohort	Daclizumab clinical study program.	MS women who became pregnant while receiving daclizumab or <=6 months after the final dose	unexposed, sick MS women who have stopped daclizumab at least 6 months before becoming pregnant.	3 months or more before pregnancy or1st trimester	38 / 6	Half-life: 21 days (7*21 days = 147 days : about 5 months). In the event of pregnancy, daclizumab was discontinued and safety monitoring continued.
Gold 2016	Worldwide Until 2015 retrospective cohort	Daclizumab clinical study program.	Clinics visits occurred every 4 weeks for daclizumab administration and safety and tolerability assessments; during the extension studies, visits were every 4–12 weeks.		3 months or more before pregnancy or1st trimester	38 / 6

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;